Earnings Call · Q4 FY2025·2026-02-26

Q4 25EPS +5.84%·Rev n/aQ3 25EPS -10.40%·Rev n/aQ2 25EPS -8.85%·Rev n/aQ1 25EPS -9.47%·Rev n/a⚠ consensus missing

Crinetics Pharmaceuticals, Inc. CRNX

Gayathri Diwakar — Head of Investor Relations

R. Struthers — Founder and Chief Executive Officer

Alan Krasner — Chief Endocrinologist

Tobin Schilke — Chief Financial Officer

−4.6%1d on move date−5.2% vs SPY3d+10.5%5d+14.9%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more CRNX calls or request research access.

More CRNX calls Browse calls Request research access